Zacks: Brokerages Anticipate Bausch Health Companies Inc (BHC) Will Post Earnings of $0.88 Per Share

Share on StockTwits

Analysts predict that Bausch Health Companies Inc (NYSE:BHC) will post earnings of $0.88 per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Bausch Health Companies’ earnings. The highest EPS estimate is $1.01 and the lowest is $0.66. Bausch Health Companies posted earnings per share of $0.98 during the same quarter last year, which would indicate a negative year over year growth rate of 10.2%. The company is expected to announce its next earnings results on Wednesday, February 27th.

On average, analysts expect that Bausch Health Companies will report full year earnings of $3.81 per share for the current fiscal year, with EPS estimates ranging from $3.60 to $3.96. For the next financial year, analysts anticipate that the firm will post earnings of $3.85 per share, with EPS estimates ranging from $3.63 to $4.14. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.84 by $0.31. Bausch Health Companies had a positive return on equity of 32.19% and a negative net margin of 40.41%. The firm had revenue of $2.14 billion during the quarter, compared to analysts’ expectations of $2.09 billion. Bausch Health Companies’s quarterly revenue was down 3.7% compared to the same quarter last year.

Several equities research analysts have recently commented on the company. Deutsche Bank set a $30.00 target price on Bausch Health Companies and gave the company a “buy” rating in a research note on Wednesday, September 12th. Cantor Fitzgerald restated a “buy” rating and issued a $32.00 price target on shares of Bausch Health Companies in a research report on Wednesday, September 12th. Zacks Investment Research upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a research report on Wednesday, October 3rd. Mizuho restated a “buy” rating and issued a $35.00 price target on shares of Bausch Health Companies in a research report on Monday, October 8th. Finally, Royal Bank of Canada set a $30.00 target price on Bausch Health Companies and gave the stock a “hold” rating in a report on Monday, October 8th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $28.18.

BHC stock traded down $0.59 during midday trading on Friday, reaching $23.66. 2,726,742 shares of the company’s stock traded hands, compared to its average volume of 3,401,804. Bausch Health Companies has a 1-year low of $14.44 and a 1-year high of $28.45. The stock has a market capitalization of $8.48 billion, a price-to-earnings ratio of 6.18, a P/E/G ratio of 0.32 and a beta of -0.28. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.14 and a quick ratio of 0.91.

In other Bausch Health Companies news, EVP Christina Ackermann sold 19,946 shares of Bausch Health Companies stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $24.98, for a total transaction of $498,251.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Joseph C. Papa bought 30,000 shares of Bausch Health Companies stock in a transaction on Friday, September 14th. The shares were acquired at an average price of $22.32 per share, for a total transaction of $669,600.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 165,000 shares of company stock worth $3,890,700. Corporate insiders own 11.54% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. ValueAct Holdings L.P. acquired a new stake in shares of Bausch Health Companies in the third quarter valued at about $462,911,000. Vanguard Group Inc. acquired a new position in Bausch Health Companies during the third quarter worth approximately $223,173,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Bausch Health Companies during the third quarter worth approximately $214,979,000. Dimensional Fund Advisors LP acquired a new position in Bausch Health Companies during the third quarter worth approximately $135,538,000. Finally, Bank of Montreal Can acquired a new position in Bausch Health Companies during the third quarter worth approximately $94,432,000. Hedge funds and other institutional investors own 50.09% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Recommended Story: What is the Consumer Price Index (CPI)?

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.